Pacira BioSciences to Acquire Flexion Therapeutics For $8.50/Share In Cash Plus One Non-tradeable Contingent Value Right Worth Up To $8/Share In Cash
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences is set to acquire Flexion Therapeutics for $8.50 per share in cash, along with a non-tradeable contingent value right worth up to $8 per share. This acquisition could impact the stock prices of both companies.
October 11, 2021 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pacira BioSciences is acquiring Flexion Therapeutics, which may impact its stock price depending on investor perception of the acquisition's strategic value.
The acquisition could be seen as a strategic move to enhance Pacira's portfolio, but the impact on PCRX's stock price will depend on how investors perceive the long-term benefits and integration risks.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Flexion Therapeutics is being acquired by Pacira BioSciences for $8.50 per share in cash, plus a contingent value right worth up to $8 per share.
The acquisition price of $8.50 per share in cash is likely to increase FLXN's stock price to align with the offer. The contingent value right adds potential additional value, making the acquisition attractive to investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100